HitGen and LoQus23 Therapeutics Partner on DNA Encoded Library for Neurodegeneration
China-based HitGen Inc. (SHA: 688222) announced a strategic partnership with UK-headquartered LoQus23 Therapeutics Ltd, leveraging...
Roche Diagnostics and Topgen Biopharm Launch Innovation Center in Chongqing
Swiss diagnostics giant Roche Diagnostics and China-based Topgen Biopharm announced the establishment of a strategic...
Hybio Pharmaceutical Signs Tech Transfer Deal with China’s CDC for COVID-19 Vaccine Peptide Sequences
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that it has signed a technology transfer...
Yunnan Baiyao and Huawei Partner on AI-Driven Drug Development
Yunnan Baiyao Group Co., Ltd (SHE: 000538), a Kunming-based pharmaceutical firm, has entered into a...
Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...
Sichuan Kelun Pharmaceutical and Merck Sharp & Dohme Corp. Ink Second ADC Licensing Deal
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that US-based Merck Sharp & Dohme...
SinoPharm CNBG’s F61 Monoclonal Antibody Receives NMPA Clinical Trial Approval
SinoPharm CNBG Wuhan Institute of Biological Products Co., Ltd’s F61, a recombinant broad-spectrum novel coronavirus...
Legend Biotech Plans USD 250M Secondary Offering to Fund CAR-T Therapy Development
China-based Legend Biotech Corporation (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T cell...
AbbVie’s Allergan Aesthetics CoolAdvantage Applicator Wins NMPA Approval
US-based AbbVie’s Allergan Aesthetics announced that it has received marketing approval from the National Medical...
Henlius Biotech’s Hanquyou Approved in Australia for HER2-Positive Cancers
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has received marketing approval from Australia’s...
Hengrui Medicine’s SHR-1802 + SHR-1316 Combo Receives NMPA Approval for Solid Tumor Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Betta Pharmaceuticals Enrolls First Patient in BPI-442096 Phase I Study for Solid Tumors
China-based Betta Pharmaceuticals (SHE: 300558) announced that the first subject has been enrolled in a...
Hengrui Medicine’s SHR-A1811 Combo Receives NMPA Approval for HER2+ NSCLC Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Ascentage Pharma Launches Olverembatinib Named Patient Program with Tanner Pharma
China-based Ascentage Pharma (HKG: 6855) announced the launch of a Named Patient Program (NPP) for...
Sirnaomics’ STP705 Receives Approval for Liver Cancer Trial in Taiwan
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced that it has received approval from...
GenFleet Therapeutics’ GFH018 Receives CTA Approval for Two Clinical Trials in China
Shanghai-based biotech company GenFleet Therapeutics announced that two clinical trial applications (CTAs) for its drug...
NMPA Approves Genuine Biotech’s Azvudine for COVID-19, Fosun Pharma Inks Licensing Deal
China’s National Medical Products Administration (NMPA) has conditionally approved HeNan Genuine Biotech Co., Ltd’s azvudine...
Chinese Pharmacists Association Releases Draft VBP Drug Management Guidelines for Public Feedback
The Chinese Pharmacists Association (CPA) has released the “National Volume-based Procurement (VBP) Drug Management Expert...
3D Medicines Files IPO Prospectus for Hong Kong Listing
China-based oncology specialist 3D Medicines has published its initial public offering (IPO) prospectus with the...
I-Mab Doses First Patient in Global Phase I Study for TJ-CD4B in Solid Tumors
I-Mab (NASDAQ: IMAB), a Nasdaq-listed company since 2020, announced that the first patient has been...